The ongoing phase 2b SunRISe-1 study is assessing TAR-200 intravesical gemcitabine delivery in patients with BCG-unresponsive high-risk NMIBC.

T cell therapy called AIC100, which targets the ICAM-1 protein, demonstrated encouraging responses and an acceptable safety profile in patients with two types of advanced thyroid cancer, according to ...

T cell therapy called AIC100, which targets the ICAM-1 protein, demonstrated encouraging responses and an acceptable safety ...